<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02528019</url>
  </required_header>
  <id_info>
    <org_study_id>Anti-athero</org_study_id>
    <nct_id>NCT02528019</nct_id>
  </id_info>
  <brief_title>Metabolic and Cardiovascular Effects of Dipeptidyl Peptidase-4 (DPP-4) or Sodium-glucose Co-transporter Type 2 (SGLT2) Inhibitors</brief_title>
  <official_title>Effects of the DPP-4 or SGLT2 Inhibitors on the Metabolic Cardiovascular Systems in Patients With Type 2 Diabetes Mellitus.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kurume University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kurume University</source>
  <brief_summary>
    <textblock>
      Inhibition of dipeptidyl peptidase-4 (DPP-4) or sodium-glucose co-transporter type 2 (SGLT2)
      has been proposed as a therapeutic target for type 2 diabetes. However, how DPP-4 inhibitors
      or SGLT2 inhibitors exert protective actions for diabetic complications in addition to their
      glucose-lowering effects remains unknown.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effects of treatment on the nominal change in arterial stiffness from baseline after 6 months of treatment as measured by cardio-ankle vascular index</measure>
    <time_frame>6 months of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in subcutaneous and visceral fat volume</measure>
    <time_frame>6 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in lipid profile including malondialdehyde-modified low-density lipoprotein and remnant-like particle cholesterol</measure>
    <time_frame>6 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in circulating inflammatory markers</measure>
    <time_frame>6 months of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Effects of the DPP-4 Inhibitors or SGLT2 Inhibitors on the Protective Actions for Diabetic Complications</condition>
  <arm_group>
    <arm_group_label>DPP-4 inhibitors</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>sitagliptin (25-100mg daily), vildagliptin (50-100mg daily), alogliptin (12.5-25mg daily), linagliptin (2.5-5mg daily), teneligliptin (20-40mg), anagliptin (100-200mg daily), saxagliptin (2.5-5mg daily) or trelagliptin (50-100mg weekly)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SGLT2 inhibitors</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ipragliflozin (50-100mg daily), dapagliflozin (5-10mg daily), luseogliflozin (2.5-5mg), tofogliflozin (20mg daily), canagliflozin (100mg daily) or empagliflozin (10-25mg daily)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glimepiride</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>glimepiride (0.5-8mg daily)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DPP-4 inhibiotors</intervention_name>
    <arm_group_label>DPP-4 inhibitors</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SGLT2 inhibitors</intervention_name>
    <arm_group_label>SGLT2 inhibitors</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glimepiride</intervention_name>
    <arm_group_label>Glimepiride</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of type 2 diabetic patients

          -  Must be able to swallow tablets

          -  never received DPP-4 inhibitors or SGLT2 inhibitors

        Exclusion Criteria:

          -  uncontrolled diabetes (fasting plasma glucose&gt;200 mg/dL)

          -  receiving insulin therapy

          -  hepatic disorders (2.5 fold or greater increases in aspartate transaminase or alanine
             transaminase levels above the upper limits of normal)

          -  inflammatory disorders

          -  neoplastic disorders

          -  recent (&lt;3months) acute coronary syndrome and stroke

          -  any acute infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nobuhiro Tahara, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Medicine, Division of Cardiovascular Medicine, Kurume University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nobuhiro Tahara, MD, PhD</last_name>
    <phone>+81-942-31-7580</phone>
    <email>ntahara@med.kurume-u.ac.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kurume University Hospital</name>
      <address>
        <city>Kurume city</city>
        <zip>830-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nobuhiro Tahara, MD, PhD</last_name>
      <phone>+81-942-31-7580</phone>
      <email>ntahara@med.kurume-u.ac.jp</email>
    </contact>
    <contact_backup>
      <last_name>Sho-ichi Yamagishi, MD, PhD</last_name>
      <phone>+81-942-31-7562</phone>
    </contact_backup>
    <investigator>
      <last_name>Nobuhiro Tahara, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2015</study_first_submitted>
  <study_first_submitted_qc>August 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2015</study_first_posted>
  <last_update_submitted>August 18, 2015</last_update_submitted>
  <last_update_submitted_qc>August 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kurume University</investigator_affiliation>
    <investigator_full_name>Nobuhiro Tahara</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Complications</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glimepiride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

